KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine test for Bladder Cancer

By In The News
January 9, 2020 in The Headlines

Recommended Posts

In The News

Posted January 9, 2020

- Share

Posted January 9, 2020

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bladder Cancer Recurrence Test. This revolutionary new test exploits a novel cancer marker...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219854
2. Jaydee
  16745
3. Kip Powick
  12211
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine test for Bladder Cancer

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support